Industry News - The Ministry of Finance and the State Administration of Taxation announced that tobacco companies will not be allowed to deduct advertising and promotional expenses from taxable income from January 1, 2026, to December 31, 2027 [3] - The People's Bank of China has introduced a plan to strengthen the management and service system for digital RMB, which will start paying interest on wallet balances at the rate of current deposits from January 1, 2026, marking a transition from "digital cash" to "digital deposit currency" [3] - The China Chain Store and Franchise Association reported that the market size of on-site food sales in supermarkets has exceeded 100 billion yuan [3] - The Asset Management Association of China reported that the total scale of public funds reached 37.02 trillion yuan by the end of November 2025, marking the eighth historical high this year [3] - The Southern Power Grid announced that the last unit of the pumped storage power station in Nanning, Guangxi, was put into operation on December 29, 2025, marking the full completion of Guangxi's first pumped storage power station [3] Company News - Ganfeng Lithium announced that it has been transferred to the procuratorate for prosecution due to suspected insider trading [5] - Kweichow Moutai announced that its controlling shareholder, Moutai Group, has completed a share buyback plan amounting to 3 billion yuan, with no increase in the market supply of Moutai 1935 in 2026 [6][6] - Longpan Technology announced that its subsidiary will reduce production for maintenance on some lithium iron phosphate production lines starting January 1, 2026 [6] - Unigroup Guowei announced plans to acquire controlling or all equity of Ruineng Semiconductor, with stock suspension [6] - ST Panda announced that it has been investigated by the China Securities Regulatory Commission for suspected violations of information disclosure [6] - Haisheng Pharmaceutical announced that its invested company has completed the first patient enrollment for the Phase II clinical trial of the innovative drug NWRD06, targeting a specific liver cancer marker [6] - Tianjian Technology expects a negative net profit for 2025 and revenue below 300 million yuan, which may lead to a delisting risk warning [6] - Tianpu Co. announced no plans to engage in artificial intelligence-related business and has not signed any framework cooperation agreements with shareholders [6] - Guodian Power announced a joint investment with CATL in the Dadu River Danba Hydropower Station project, with a total dynamic investment of 15.273 billion yuan [6] - Hongwei Technology signed a strategic cooperation agreement with a leading domestic company in the transmission field to jointly research GaN power semiconductor devices [6] - 吉祥航空 plans to purchase 25 Airbus A320 series aircraft for 4.1 billion USD, with delivery scheduled between 2028 and 2032 [6][6] - Spring Airlines plans to purchase 30 Airbus A320neo series aircraft for no more than 4.128 billion USD [6][6] - Huazhi Co. announced the termination of the acquisition of 51% of Zhongke Huilian [6] - Wenkong Energy announced a stock suspension for investigation due to significant short-term price increases [6] - Roman Co. signed a contract for a computing power service project worth approximately 156 million yuan [6] - International Composite announced plans to invest 1.693 billion yuan in a project to produce 36 million meters of high-frequency high-speed electronic fiber cloth annually [6]

Key Points - Guizhou Moutai's controlling shareholder, Moutai Group, has completed a share buyback plan, acquiring 2,071,359 shares for a total of 3 billion yuan, increasing its stake to 56.63% of the total share capital [1] - Juneyao Airlines plans to purchase 25 Airbus A320 series aircraft for a total of 4.1 billion USD, with deliveries scheduled between 2028 and 2032 [1] - ST Panda is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [1] - Huali Co. has terminated its plan to acquire a 51% stake in Zhongke Huilian due to a lack of consensus on key transaction terms [1][2] - China Duty Free Group's subsidiary has signed a contract for a duty-free project at Beijing Capital International Airport, covering an area of 10,646.74 m², with a guaranteed operating fee of 480.27 million yuan in the first year [3] - Haisheng Pharmaceutical's invested company has initiated Phase II clinical trials for NWRD06, a novel RNA drug targeting GPC3 for liver cancer, marking a significant milestone in cancer treatment [3] - WISCO Development is planning to acquire stakes in WISCO Mining and Luzhong Mining through asset swaps and cash payments, leading to a temporary suspension of its stock [4] - Yonghui Supermarket intends to publicly sell a 28.095% stake in its subsidiary Yonghui Cloud Gold Technology [5] - Shanxi Expressway plans to acquire a 15% stake in Shanxi Transportation Industry Development Group for 74.8 million yuan [5] - China Energy Construction's subsidiary has won a 6.864 billion yuan ecological comprehensive governance project [5]

Core Viewpoint - The announcement highlights the initiation of the Phase II clinical trial for NWRD06, a novel nucleic acid drug developed by Nuo Wei Biotechnology, which targets liver cancer recurrence post-surgery and represents a significant advancement in cancer treatment [1][2]. Group 1: Clinical Development - The Phase II clinical trial for NWRD06 has officially started at the Chinese Academy of Medical Sciences Cancer Hospital, with the first subject enrolled and treated [1]. - NWRD06 is the world's first therapeutic nucleic acid drug targeting the specific liver cancer marker GPC3, entering Phase II clinical trials [1]. Group 2: Mechanism and Potential - NWRD06 operates by activating specific T-cell immunity to eliminate tumor cells, showcasing an innovative mechanism that could potentially expand its application to early-stage cancer treatment [1]. - The drug may also have the potential to be combined with existing treatments for advanced liver cancer, such as interventional therapies and immune checkpoint inhibitors like PD-1 inhibitors [1]. Group 3: Clinical Value - The Phase I clinical study of NWRD06 has been completed, demonstrating its core value in precisely identifying tumor cells and addressing micro-lesions that are inaccessible to surgical treatment, while sparing normal tissues [2]. - The successful initiation of the Phase II trial marks a significant step towards clinical application, potentially offering a safe and non-invasive option for preventing recurrence in liver cancer patients, thereby improving survival rates [2].

Core Viewpoint - The company Haishang Pharmaceutical (002099.SZ) has announced the initiation of the Phase II clinical trial for its innovative nucleic acid drug NWRD06, aimed at preventing postoperative recurrence of liver cancer, marking a significant advancement in cancer treatment [1][2]. Group 1 - Haishang Pharmaceutical's subsidiary, Beijing Guoxin Zhongshu Investment Management Co., has informed the company about the participation in the clinical trial of NWRD06, which has successfully enrolled its first subject [1]. - NWRD06 is the world's first therapeutic nucleic acid drug targeting the specific liver cancer marker GPC3, currently in Phase II clinical trials, showcasing an innovative mechanism that activates specific T-cell immunity to eliminate tumor cells [1]. - The potential applications of NWRD06 may extend beyond postoperative recurrence to early-stage cancer treatment and possibly even cirrhosis, indicating a biologically rational expansion of its indications [1]. Group 2 - The Phase I clinical study of NWRD06 has been completed at the Chinese Academy of Medical Sciences Cancer Hospital, emphasizing its core value in precisely identifying tumor cells and addressing micro-lesions that are inaccessible to surgical treatment [2]. - The successful launch of the Phase II clinical trial and the enrollment of the first subject represent a significant step towards clinical application, potentially offering a safe and non-invasive option for postoperative liver cancer patients to prevent recurrence and improve survival rates [2].

Core Viewpoint - Haisheng Pharmaceutical (002099.SZ) has announced the initiation of the Phase II clinical trial for its innovative nucleic acid drug NWRD06, aimed at preventing postoperative recurrence of liver cancer, developed by its investee company, Nuo Wei Biotechnology [1] Group 1 - Haisheng Pharmaceutical received a notification from its fund management subsidiary, Beijing Guoxin Zhongshu Investment Management Co., Ltd. [1] - The clinical trial for NWRD06 has officially started at the Cancer Hospital of the Chinese Academy of Medical Sciences [1] - The first subject has been enrolled and has received the initial dose in the trial [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）近日收到旗下产业基金管 理人北京国信中数投资管理有限公司出具的《通知函》。公司获悉北京国信海翔 股权投资合伙企业（有限合伙）（以下简称"国信海翔"）参投公司诺未生物技 术（无锡）有限公司（以下简称"诺未生物"）自主研发的全球首款肝癌术后预 防复发核酸新药 NWRD06 的Ⅱ期临床试验在中国医学科学院肿瘤医院正式启动， 并已完成首例受试者入组及首次给药。现将相关情况公告如下： 一、NWRD06 注射液的基本情况 1、药物名称：NWRD06 裸质粒 DNA 注射液 证券代码：002099 证券简称：海翔药业 公告编号：2025-059 浙江海翔药业股份有限公司 关于参投公司创新药 NWRD06 注射液完成Ⅱ期临床首例受试者入 组的自愿性信息披露公告 中国是全球肝癌患者数量最多的国家，也是全球最大的肝癌药物市场之一。 根据弗若斯特沙利文分析，中国肝癌药物市场规模从 2016 年的 30.5 亿元增长至 2020 年的 71.5 亿元，年复合增长率达 23.7%。随着更多创新药 ...

Core Viewpoint - Haishang Pharmaceutical (002099) has announced the initiation of a Phase II clinical trial for its innovative nucleic acid drug NWRD06, aimed at preventing postoperative recurrence of liver cancer, marking a significant advancement in cancer treatment [1] Group 1: Company Developments - The company received a notification from its subsidiary fund manager, Beijing Guoxin Zhongshu Investment Management Co., Ltd. [1] - The investment partnership, Beijing Guoxin Haishang Equity Investment Partnership (Limited Partnership), is participating in the clinical trial of NWRD06 [1] - The trial has officially started at the Chinese Academy of Medical Sciences Cancer Hospital, with the first subject enrolled and administered the drug [1]

Policy Developments - The National Health Commission and five other departments issued guidelines to strengthen the construction of specialty departments in grassroots medical institutions, aiming to enhance service quality and meet diverse health needs by 2030 [2][3] - The initiative is part of the "Strengthening Grassroots" policy focus, emphasizing the transition from merely having medical services to improving their quality [2] Drug and Device Approvals - Haixiang Pharmaceutical announced that its invested company, Nuo Wei Biotechnology, has initiated the Phase II clinical trial for China's first on-demand tumor therapeutic vaccine, NWRD08, with the first subject enrolled [4][5] - NWRD08 targets HPV16/18 positive cervical high-grade squamous intraepithelial lesions (HSIL) and has shown over 80% efficacy in clearing HPV or achieving pathological downgrade in Phase I trials [5] Capital Markets - Baiyunshan's subsidiary, Guangzhou Pharmaceutical, plans to acquire 100% equity of Zhejiang Medical Industry Co., Ltd. for 500.5 million yuan, pending antitrust review [8][9] Industry Events - The National Medical Insurance Administration announced an early allocation of 416.6 billion yuan for basic medical insurance subsidies and construction funds for 2026 [11] - Research results on the weight loss and diabetes drug, Masitide, were published in the prestigious journal Nature, marking a significant achievement for Chinese biotechnology in the global market [12] - Eli Lilly reported promising results from the Phase III EMBER-3 trial of Imlunestrant, showing a 38% reduction in disease progression risk for patients with ESR1 mutations [13] Other Developments - South Korea's President instructed the Ministry of Health and Welfare to advance the inclusion of hair loss treatment in medical insurance, fulfilling a campaign promise [14] - Ladder Medical successfully completed its second invasive brain-computer interface clinical trial, enabling a high-level paraplegic patient to control a smart wheelchair and robotic dog [15]

Capital Operations - Shen Cheng Jiao plans to raise no more than 1.8 billion yuan through a private placement for the research and large-scale application of low-altitude and autonomous driving intelligent transportation equipment and related projects [2] - Ding Gu Ji Chuang's invested company Hang Ju Technology has developed the WS series flexible reusable thermal protection materials, which have been applied to the Blue Arrow Aerospace Zhuque-3 rocket body [2] - Zhen You Technology has ongoing ground core network development projects in both high-orbit and low-orbit satellite communication fields [2] Investment and Operations - Zhongjin Company plans a stock swap merger with Dongxing Securities and Xinda Securities, with stock trading resuming on December 18 [1] - Beiqi Blue Valley aims to continue developing L3 models in the mid-to-high-end brand segment, with some L3 model products currently in the development stage [1] - Xingmin Zhitong's communication domain controller is currently being used in L3 and L4 autonomous vehicles, including Robotaxi and unmanned logistics vehicles [1] Contracts and Collaborations - Pudong Construction's subsidiary recently won contracts totaling 1.649 billion yuan [1] - China Duty Free Group's wholly-owned subsidiary signed a contract for the transfer of duty-free store project operating rights, planning to invest 102 million yuan to establish a joint venture with Shanghai Airport [1] - Shanghai Airport signed a contract with Dufry and China Duty Free Group for the transfer of duty-free store project operating rights, with Dayang Shanghai not renewing the contract [1] - China CRRC and its subsidiaries recently signed contracts totaling 53.31 billion yuan, with wind power and energy storage equipment sales contracts amounting to approximately 16.65 billion yuan [1] Performance - China Nuclear Construction reported a cumulative operating income of 92.03 billion yuan by November 2025 [4] Share Buybacks - Shibao Testing's executives plan to increase their holdings of company shares by 8 million to 12 million yuan [4]

Core Viewpoint - Haisheng Pharmaceutical announced the initiation of the Phase II clinical trial for China's first on-demand tumor therapeutic vaccine, NWRD08 injection, developed by its invested company, Nuo Wei Biotechnology [2] Group 1 - Haisheng Pharmaceutical received a notification from its fund management subsidiary, Beijing Guoxin Zhongshu Investment Management Co., Ltd. [2] - The clinical trial for NWRD08 has officially started at Peking Union Medical College Hospital and several other hospitals [2] - The first subject has been enrolled and administered the vaccine as part of the clinical trial [2]